Sign In
Buy STVN
$19.85
-0.350 (-1.73%)
At Close: Jul 31, 2026
Stevanato: Recovery Underway, Buy Confirmed
01:53am, Sunday, 22'nd Jun 2025
Q1 results exceeded expectations, driven by strong Biopharmaceutical and Diagnostic Solutions growth and margin expansion from scaling new facilities. 2025 guidance was reaffirmed despite FX headwinds
USNA vs. STVN: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 18'th Jun 2025
Investors looking for stocks in the Medical - Drugs sector might want to consider either USANA Health Sciences (USNA) or Stevanato Group (STVN). But which of these two stocks is more attractive to val
GRFS vs. STVN: Which Stock Is the Better Value Option?
12:46pm, Monday, 02'nd Jun 2025
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang fo
Stevanato Group S.p.A. (STVN) Q1 2025 Earnings Call Transcript
04:45pm, Saturday, 10'th May 2025
Stevanato Group S.p.A. (NYSE:STVN ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Lisa Miles - SVP & Investor Relations Franco Stevanato - Chairman & Chief Executive Offi
Stevanato Group to Participate in Upcoming Investor Conferences
04:03pm, Friday, 09'th May 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
Stevanato Group (STVN) Q1 Earnings and Revenues Top Estimates
08:50am, Thursday, 08'th May 2025
Stevanato Group (STVN) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $0.09 per share a year ago.
Stevanato Group Reports Revenue of €256.6 Million for the First Quarter of 2025
06:37am, Thursday, 08'th May 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?
12:46pm, Tuesday, 06'th May 2025
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Sandoz Group AG Sponsored ADR (SDZNY) and Stevanato Group (STVN). But which of these two stocks presents i
Stevanato S p A : PWC Stevanato Group SpA Report on the Audit of the Consolidated Financial Statements
07:02am, Monday, 28'th Apr 2025
Independent auditor's report in accordance with article 14 of Legislative Decree No. 39 of 27 January 2010 To the shareholders of Stevanato Group SpA aAdsList.push('Article'); aAdsListSize.push([300,
Stevanato S p A : PWC Stevanato Group SpA Report on the Audit of the Financial Statements
07:02am, Monday, 28'th Apr 2025
Independent auditor's report in accordance with article 14 of Legislative Decree No. 39 of 27 January 2010 To the shareholders of Stevanato Group SpA aAdsList.push('Article'); aAdsListSize.push([300,
Stevanato S p A : Holding Srl Slate of Candidate Directors
07:02am, Monday, 28'th Apr 2025
STEVANATO HOLDING S.R.L. FTE 'ANATO GROLW S.P.A. aAdsList.push('Article'); aAdsListSize.push([300, 250]); aAdsListCA.push(null); 4"In MOLINELLA. 1.7, 35017 PiOMBINO DESE - PADOVA ITALY Pioinbino Dese.
Stevanato S p A : Group SpA ESG Report 2024
07:02am, Monday, 28'th Apr 2025
Sustainability Report 2024 Stevanato Group Sustainability Economic Value Innovation Human Capital Supply Chain Environment Local Communities aAdsList.push('Article'); aAdsListSize.push([300, 250]); aA
Stevanato Group to Report First Quarter 2025 Financial Results on May 8, 2025
05:15pm, Thursday, 24'th Apr 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
Stevanato Group to Participate in the KeyBanc Capital Markets Virtual Healthcare Forum
04:30pm, Tuesday, 11'th Mar 2025
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology,
Stevanato: Ramping Syringe Demand, Buy Confirmed
02:37pm, Sunday, 09'th Mar 2025
Stevanato's 2024 revenue reached €1.1 billion, surpassing analyst expectations. This growth was driven by Biopharmaceutical and Diagnostic Solutions, despite a challenging year with inventory issues
